Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications
Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications
复制标题
DOI：
10.1002/mds.20331
复制
发表时间：
2005-03-01
影响因子：
8.6
通讯作者：
Handforth, A
中科院分区：
文献类型：
--
作者：
Martin, FC;Le, AT;Handforth, A
No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti-ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20-minute epochs. The motion power over the tremor frequency bandwidth (8-12 Hz in rats 10-16 Hz in mice) was divided by the motion power over the full motion frequency range (0-15 Hz in rats; 0-34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline-induced tremor. We propose that, with this methodology, harmaline-induced tremor may be useful as a preclinical method to identify potential medications for ET. (c) 2004 Movement Disorder Society.
